Companies Fate Therapeutics Inc
Fate Therapeutics (FATE): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Fate Therapeutics Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,986,615FY2023
- $3,584,600FY2024
- $2,248,568FY2025
CEO total pay was $2,248,568 in fiscal 2025, down from $3,584,600 in fiscal 2024.
FY2025: salary $600,000 · bonus $0 · stock awards $0 · option awards $1,283,868
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Bahram Valamehr | $600,000 | $0 | $0 | $1,283,868 | $360,000 | $0 | $4,700 | $2,248,568 |
| President, Chief Executive Officer and Director | ||||||||
| Cindy Tahl | 520,000 | 0 | 92,400 | 286,896 | 208,000 | 0 | 4,700 | 1,111,996 |
| Chief Legal & Compliance Officer and Corporate Secretary | ||||||||
| Kamal Adawi | 99,000 | 0 | 115,500 | 456,000 | 39,600 | 0 | 4,700 | 714,800 |
| Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Bahram Valamehr | $2,248,568 | $3,584,600 | $2,986,615 | ↓ −1,336,032 |
| Cindy Tahl | 1,111,996 | 3,421,100 | 2,824,498 | ↓ −2,309,104 |
| Kamal Adawi | 714,800 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Each year, the Compensation Committee reviews the Company's compensation policies and programs to ensure that these policies and programs enhance shareholder value, align pay and performance, and attract and retain top executive talent.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon's Human Capital Solutions practice (Radford) |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Cindy Tahl | Option | — | — | — | — | — | $286,896 |
| Kamal Adawi | RSU | — | — | — | — | — | 115,500 |
| Cindy Tahl | RSU | — | — | — | — | — | 92,400 |
| Bahram Valamehr | Option | — | — | — | — | — | 1,283,868 |
| Kamal Adawi | Option | — | — | — | — | — | 456,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Cindy Tahl | $92,400 | $0 | $286,896 | 0.0% |
| Kamal Adawi | 115,500 | 0 | 456,000 | 0.0% |
| Bahram Valamehr | 0 | 0 | 1,283,868 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Bahram Valamehr | Option | 1,106 | 39.87 | — |
| Cindy Tahl | Option | 1,106 | 39.87 | — |
| Cindy Tahl | Option | 11,806 | 6.77 | — |
| Bahram Valamehr | Option | 12,501 | 6.77 | — |
| Cindy Tahl | Option | 153,478 | 6.76 | — |
| Bahram Valamehr | Option | 162,501 | 6.76 | — |
| Cindy Tahl | Option | 190,975 | 1.32 | — |
| Kamal Adawi | Option | 375,000 | 1.54 | — |
| Bahram Valamehr | Option | 902,779 | 1.25 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Matthew C. AbernethyIndependent · Audit (Chair) · Newly elected | $35,440 | $0 | $116,172 | — | $0 | $151,612 |
| William H. RastetterIndependent · Board Chair · Audit | 84,896 | 0 | 58,086 | — | 0 | 142,982 |
| Robert S. EpsteinIndependent · Audit · Compensation · Nominating/Governance (Chair) | 65,625 | 0 | 58,086 | — | 0 | 123,711 |
| Karin JoossIndependent · Compensation (Chair) · Science & Technology | 60,875 | 0 | 58,086 | — | 0 | 118,961 |
| Shefali AgarwalIndependent · Nominating/Governance · Science & Technology (Chair) | 57,000 | 0 | 58,086 | — | 0 | 115,086 |
| Yuan XuIndependent · Compensation · Science & Technology | 53,438 | 0 | 58,086 | — | 0 | 111,524 |
| Michael LeeIndependent · Science & Technology | 46,000 | 0 | 58,086 | — | 0 | 104,086 |
| Neelufar MozaffarianIndependent · Departed during FY | 38,250 | 0 | 58,086 | — | 0 | 96,336 |
| John D. MendleinIndependent · Departed during FY | 34,500 | 0 | 58,086 | — | 0 | 92,586 |
| Timothy P. CoughlinIndependent · Not standing for re-election · Departed during FY | 26,225 | 0 | — | — | 0 | 26,225 |
| Laura J. HamillNewly elected | 0 | 0 | 0 | — | 0 | 0 |
| Bahram ValamehrEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $502,249 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $502,249 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Fate Therapeutics as a peer
Companies that benchmark against FATE
12 companies name FATE as a compensation peer
The list of companies that name FATE as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Fate Therapeutics Inc | 2025 | Bahram Valamehr | $600,000 | $0 | $1,283,868 | $360,000 | $2,248,568 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-12 | 59,168,689 | 1,808,669 | 73,304 | 97.03% | Passed |
| 2024 | 2024-06-07 | 65,401,635 | 25,615,148 | 433,964 | 71.86% | Passed |
| 2023 | 2023-06-06 | 73,720,442 | 2,955,503 | 61,938 | 96.15% | Passed |
| 2022 | 2022-06-09 | 75,409,609 | 9,055,375 | 281,395 | 89.28% | Passed |
| 2021 | 2021-06-02 | 75,621,321 | 1,509,267 | 34,083 | 98.04% | Passed |
| 2020 | 2020-05-01 | 56,002,884 | 3,656,407 | 55,166 | 93.87% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-12 | 97.03%a |
| 2024 | 2024-06-07 | 71.86%b |
| 2023 | 2023-06-06 | 96.15%c |
a. Approved under the standard stated in the filing — “If 2 Table of Contents you abstain from voting on this matter, your shares will not be counted as "votes cast" with respect to such matter, and the abstention will have no effect on the proposal.”.
b. Approved under the standard stated in the filing — “If you abstain from voting on this matter, your shares will not be counted as "votes cast" with respect to such matter, and the abstention will have no effect on the proposal.”.
c. Approved under the standard stated in the filing — “If you abstain from voting on this matter, your shares will not be counted as "votes cast" with respect to such matter, and the abstention will have no effect on the proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| William H. Rastetter | Director | 2026-05-05 | A | 25,000 | $2 | $42,250 | Common | Form 4 ↗ |
| William H. Rastetter | Director | 2026-05-05 | A | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert S. Epstein | Director | 2026-05-05 | A | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert S. Epstein | Director | 2026-05-05 | A | 25,000 | 2 | 42,250 | Common | Form 4 ↗ |
| Cindy Tahl | See Remarks | 2026-05-06 | A | 122,220 | 1 | 161,330 | Common | Form 4 ↗ |
| Cindy Tahl | See Remarks | 2026-05-06 | D | 44,444 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cindy Tahl | See Remarks | 2026-05-06 | D | 122,220 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cindy Tahl | See Remarks | 2026-05-06 | A | 44,444 | 1 | 46,666 | Common | Form 4 ↗ |
| Bahram Valamehr | Director | 2026-05-20 | D | 28,946 | 2 | 54,482 | Common, open-market sale | Form 4 ↗ |
| Cindy Tahl | See Remarks | 2026-05-20 | D | 25,590 | 2 | 48,084 | Common, open-market sale | Form 4 ↗ |
| William H. Rastetter | Director | 2026-06-12 | A | 87,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew C. Abernethy | Director | 2026-06-12 | A | 87,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shefali Agarwal | Director | 2026-06-12 | A | 87,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Redmile Group, LLC | Director | 2026-06-12 | A | 87,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yuan Xu | Director | 2026-06-12 | A | 87,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2026-06-12 | A | 175,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert S. Epstein | Director | 2026-06-12 | A | 87,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karin Jooss | Director | 2026-06-12 | A | 87,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Lee | Director | 2026-06-12 | A | 87,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cindy Tahl | See Remarks | 2026-08-04 | D | 38,800 | 2 | 95,405 | Common, open-market sale | Form 4 ↗ |
| Bahram Valamehr | Director | 2026-08-04 | D | 43,947 | 2 | 108,101 | Common, open-market sale | Form 4 ↗ |
| Kamal Adawi | Chief Financial Officer | 2026-11-03 | D | 6,582 | 2 | 13,525 | Common, open-market sale | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (50 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Bahram Valamehr. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table” · page 38. As printed: 2,248,568. View filing ↗
- Section 01, Cindy Tahl. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 1,111,996. View filing ↗
- Section 01, Kamal Adawi. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 714,800. View filing ↗
- Section 03, Cindy Tahl Option. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Kamal Adawi RSU. DEF 14A, filed 2026-04-24. Section “FOR THE APPROVAL, ONNON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY&” · grants of plan-based awards table. View filing ↗
- Section 03, Cindy Tahl RSU. DEF 14A, filed 2026-04-24. Section “FOR THE APPROVAL, ONNON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY&” · grants of plan-based awards table. View filing ↗
- Section 03, Bahram Valamehr Option. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Kamal Adawi Option. DEF 14A, filed 2026-04-24. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-02-26. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Matthew C. Abernethy. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 151,612. View filing ↗
- Section 08, William H. Rastetter. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 142,982. View filing ↗
- Section 08, Robert S. Epstein. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 123,711. View filing ↗
- Section 08, Karin Jooss. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 118,961. View filing ↗
- Section 08, Shefali Agarwal. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 115,086. View filing ↗
- Section 08, Yuan Xu. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 111,524. View filing ↗
- Section 08, Michael Lee. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 104,086. View filing ↗
- Section 08, Neelufar Mozaffarian. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 96,336. View filing ↗
- Section 08, John D. Mendlein. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 92,586. View filing ↗
- Section 08, Timothy P. Coughlin. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 26,225. View filing ↗
- Section 08, Laura J. Hamill. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Bahram Valamehr. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, William H. Rastetter 2026-05-05. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William H. Rastetter 2026-05-05. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert S. Epstein 2026-05-05. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert S. Epstein 2026-05-05. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cindy Tahl 2026-05-06. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cindy Tahl 2026-05-06. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cindy Tahl 2026-05-06. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cindy Tahl 2026-05-06. Form 4, filed 2026-05-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bahram Valamehr 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cindy Tahl 2026-05-20. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William H. Rastetter 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew C. Abernethy 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shefali Agarwal 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Redmile Group, LLC 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yuan Xu 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura J. Hamill 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert S. Epstein 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karin Jooss 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Lee 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cindy Tahl 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bahram Valamehr 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kamal Adawi 2026-11-03. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-15. Item 5.07 · say-on-pay result. As reported: 97.03% (votes for as printed: 59,168,689). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: 71.86% (votes for as printed: 65,401,635). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-09. Item 5.07 · say-on-pay result. As reported: 96.15% (votes for as printed: 73,720,442). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 502,249 + equity 0 + all other 0 = 502,249, summed across the director compensation table rows.
- Fate Therapeutics Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Fate Therapeutics Inc's own proxy. As printed: 2,248,568. View filing ↗